Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220

Journal of Immunology

Volumn 167, Issue 3, 2001, Pages 1490-1499

  Sarrias, M R ^a   Franchini, S ^a   Canziani, G ^a   Argyropoulos, E ^a   Moore, W T ^a   Sahu, A ^a   Lambris, J D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C2 RECEPTOR; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3C; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENT RECEPTOR; GLYCOPROTEIN; GLYCOPROTEIN GP 220; GLYCOPROTEIN GP 350; MEMBRANE PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; BINDING SITE; CHEMICAL REACTION KINETICS; COMPLEMENT FIXATION; COMPLEX FORMATION; LIGAND BINDING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; PRIORITY JOURNAL; RAMAN SPECTROMETRY; RECEPTOR BINDING;

EID: 0035423431     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.167.3.1490     Document Type: Article

References (60)

1. Expression of EBV/C3d receptors on T cells: Biological significance
2. Complement receptors
3. Complement receptor type 1 (C3/C4b receptor; CD35) and complement receptor type 2 (C3d/Epstein-Barr virus receptor; CD21)
4. Complement receptors
5. Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor
6. The regulators of complement activation (RCA) gene cluster
7. The role of complement and complement receptors in induction and regulation of immunity
8. Contribution of the innate immune system to autoimmune diabetes: A role for the CR1/CR2 complement receptors
9. Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration
10. Modulation of mouse complement receptor-1 and receptor-2 suppresses anti-body responses in vivo
11. Linkages of innate and adaptive immunity
12. C3d of complement as a molecular adjuvant: Bridging innate and acquired immunity
13. C3d enhancement of antibodies to hemagglutinin accelerates protection against influenza virus challenge
14. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: Sequence homology of gp350 and C3 complement fragment C3d
15. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis
16. gp140, the C3d receptor of human B lymphocytes, is also the Epstein-Barr virus receptor
17. C3 synthetic peptides support growth of human CR2-positive lymphoblastoid B cells
18. CR2 ligands modulate human B cell activation
19. Enhanced and sustained activation of human B cells by anti-immunoglobulin conjugated to the EBV glycoprotein gp350
20. Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2
21. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides: At least two distinct sites are necessary for ligand-receptor interaction
22. Soluble gp350/220 and deletion mutant glycoprotein block Epstein-Barr virus adsorption to lymphocytes
23. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement
24. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21)
25. A 16 amino acid synthetic peptide derived from human C3d triggers proliferation and specific tyrosine phosphorylation of transformed CR2-positive human lymphocytes and of normal resting lymphocytes-B
26. Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide
27. Interaction of iC3b with recombinant isotypic and chimeric forms of CR2
28. Mutation of residues in tine C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2
29. X-ray crystal structure of C3d: A C3 fragment and ligand for complement receptor 2
30. Structure-guided identification of C3d residues essential for its binding to complement receptor 2 (CD21)
31. Induction of peri-insulitis but not diabetes in islet transplants expressing a single foreign antigen: A multi-stage model of disease
32. Interaction between Epstein-Barr virus and a T cell line (HSB-2) via a receptor phenotypically distinct from complement receptor type 2
33. Enhanced secretion from insect cells of a foreign protein fused to the honeybee melittin signal peptide
34. The complete genome sequence of Escherichia coli K-12
35. Biotinyl-5′-adenylate synthesis catalyzed by Escherichia coli repressor of biotin biosynthesis
36. Release of endogenous C3b inactivator from lymphocytes in response to triggering membrane receptors for β1H globulin
37. Purification of human C3b inactivator by monoclonal-antibody affinity chromatography
38. Structural and functional analysis of the complement component factor H with the use of different enzymes and monoclonal antibodies to factor H
39. Human C3 and C5: Subunit structure and modification by trypsin and C42-C423
40. Identification of the C3b receptor-binding domain in third component of complement
41. Interaction of vaccinia virus complement control protein with human complement proteins: Factor I-mediated degradation of C3b to iC3b(1) inactivates the alternative complement pathway
42. Growing protein-doped sinaptic acid crystals for laser-desorption: An alternative preparation method for difficult samples 231
43. Specificity of the thioester-containing reactive site of human C3 and its significance to complement activation
44. The internal thioester and the covalent binding properties of the complement proteins C3 and C4
45. Binding kinetics, structure-activity relationship, and biotransformation of the complement inhibitor compstatin
46. Kinetics and thermodynamics of virus binding to receptor: Studies with rhinovirus, intercellular adhesion molecule-1 (ICAM-1), and surface plasmon resonance
47. Analysis of the interaction between human interleukin-5 and the soluble domain of its receptor using a surface plasmon resonance biosensor
48. Purification and quantification of recombinant Epstein-Barr viral glycoproteins gp350/220 from Chinese hamster ovary cells
49. Expression of Epstein-Barr virus membrane antigen-gp350/220 in E. coli and in insect cells
50. A minimal peptide substrate in biotin holoenzyme synthetase-catalyzed biotinylation
51. Analysis of Epstein-Barr virus-binding sites on complement receptor 2 (CR2/CD21) using human-mouse chimeras and peptides: At least two distinct sites are necessary for ligand-receptor interaction
52. Characterization of a complement receptor 2 (CR2, CD21) ligand binding site for C3: An initial model of ligand interaction with two linked short consensus repeat modules
53. Studies on the interaction of C3dg with CR2
54. Experimental design for analysis of complex kinetics using surface plasmon resonance
55. Spontaneous thioester bond formation in α2-macroglobulin, C3 and C4
56. Hydrodynamic, electron microscopic and ligand binding analysis of the Epstein-virus/C3dg receptor (CR2)
57. Selective inhibition of functional sites of cell-bound C3b by hybridoma-derived antibodies
58. Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation: Relationship between immune complex levels, state of C3, and numbers of receptors for C3b
59. Conformational differences between surface-bound and fluid-phase complement-component-C3 fragments: Epitope mapping by cDNA expression